Gomiliximab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Gomiliximab ?
Monoclonal antibody
Type Whole antibody
Source Chimeric (primate/human)
Target CD23
Clinical data
Legal status
?
Identifiers
CAS number 357613-86-6 N
ATC code None
UNII 8Z13S29R5A YesY
KEGG D06463 YesY
Chemical data
Formula ?
 N (what is this?)  (verify)

Gomiliximab is a monoclonal antibody acting as an immunosuppressive drug for the treatment of allergic asthma. It targets the low affinity IgE receptor (FcεRII or CD23).[1] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[1]

This drug was developed by IDEC Pharmaceuticals Corporation.

References[edit]

  1. ^ a b Statement On A Nonproprietary Name Adopted By The Usan Council - Gomiliximab, American Medical Association.